- Open
- 1.15
- High
- 1.15
- Low
- 1.15
- Close
- 1.15
- Change
- -0.05 (-4.35%)
- Volume
- 16,086
| 4 Aug 2026 | 07:00:06 | MT-RNR1 test implemented in the Netherlands |
| 3 Aug 2026 | 07:00:09 | New UK clinical guideline for MT-RNR1 testing |
| 14 Jul 2026 | 07:00:05 | Board Appointment |
| 13 Jul 2026 | 07:00:09 | Trading Update |
| 10 Jul 2026 | 07:00:04 | UK Minister highlights pharmacogenetic testing |
| 22 Dec 2025 | Annual Report and Accounts (to 2025-06-30) | |
| 23 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 2 Jan 2024 | Annual Report and Accounts (to 2023-06-30) |
Genedrive plc develops and commercializes rapid pharmacogenetic testing solutions aimed at improving patient outcomes through personalized medicine. The company offers a near-patient testing platform that identifies genetic variants affecting drug response, enabling healthcare professionals to make informed treatment decisions quickly. Its primary products include the Genedrive® MT-RNR1 ID Kit, which helps prevent antibiotic-induced hearing loss in neonates, and the Genedrive® CYP2C19 ID Kit, designed for optimizing antiplatelet therapy in stroke patients. Genedrive operates primarily in the UK and collaborates with the National Health Service (NHS) to enhance clinical care pathways.
| 4 Aug 2026 | 07:00:06 | MT-RNR1 test implemented in the Netherlands |
| 3 Aug 2026 | 07:00:09 | New UK clinical guideline for MT-RNR1 testing |
| 14 Jul 2026 | 07:00:05 | Board Appointment |
| 13 Jul 2026 | 07:00:09 | Trading Update |
| 10 Jul 2026 | 07:00:04 | UK Minister highlights pharmacogenetic testing |
| 22 Dec 2025 | Annual Report and Accounts (to 2025-06-30) | |
| 23 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 2 Jan 2024 | Annual Report and Accounts (to 2023-06-30) |
Genedrive plc develops and commercializes rapid pharmacogenetic testing solutions aimed at improving patient outcomes through personalized medicine. The company offers a near-patient testing platform that identifies genetic variants affecting drug response, enabling healthcare professionals to make informed treatment decisions quickly. Its primary products include the Genedrive® MT-RNR1 ID Kit, which helps prevent antibiotic-induced hearing loss in neonates, and the Genedrive® CYP2C19 ID Kit, designed for optimizing antiplatelet therapy in stroke patients. Genedrive operates primarily in the UK and collaborates with the National Health Service (NHS) to enhance clinical care pathways.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £304m | -0.1% | |
| £27m | +0.6% | |
| £12m | +0.5% | |
| £12m | +2.1% | |
| £10m | -0.6% | |
GDRGenedrive PLC | £7m | -0.0% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £304m | -0.1% | |
| £27m | +0.6% | |
| £12m | +0.5% | |
| £12m | +2.1% | |
| £10m | -0.6% | |
GDRGenedrive PLC | £7m | -0.0% |